Kroger Pharmacy vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kroger-owned in-store pharmacy chain with 2,200 locations in supermarket banners; prescription services integrated with grocery loyalty program competing with CVS and Walgreens.
About
Kroger Pharmacy is the pharmacy division of The Kroger Co., operating approximately 2,200 in-store pharmacies within Kroger supermarkets and Kroger-owned banner stores (Fred Meyer, King Soopers, Ralphs, Harris Teeter, Smith's, and others) across the United States — making it one of the largest pharmacy chains in the country. Part of Kroger (NYSE: KR), the nation's largest pure-play supermarket chain with approximately $150 billion in annual revenue, Kroger Pharmacy benefits from the combination of convenient supermarket co-location and Kroger's pharmaceutical purchasing scale.\n\nKroger Pharmacy provides prescription filling, immunization services, medication therapy management, and specialty pharmacy for complex medications. The pharmacy integrates with Kroger's loyalty program (Kroger Plus Card) to provide fuel points for pharmacy purchases and to connect prescription refill reminders with grocery shopping behavior. Kroger's OptUP nutrition scoring and health programs connect pharmacy and grocery to support customer health goals.\n\nIn 2025, Kroger Pharmacy competes with CVS Health, Walgreens, Walmart Pharmacy, and mail-order pharmacies for prescription market share. The retail pharmacy sector faces significant pressure from PBM reimbursement cuts and the shift to 90-day mail-order supply, which has forced pharmacy closures across the industry. Kroger's merger with Albertsons (blocked by FTC in February 2024) would have significantly expanded Kroger's pharmacy network, but the blocked merger leaves Kroger competing at current scale. The 2025 strategy focuses on integrating pharmacy into Kroger's digital health ecosystem, expanding specialty pharmacy capabilities, and leveraging Kroger Health data analytics for population health management programs.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.